本帖最后由 老马 于 2013-3-13 13:43 编辑
: Y7 ?. ?& o; _$ K. |# a/ _/ e' R4 G6 A
健择（吉西他滨）+顺铂+阿瓦斯汀
8 J4 Z- S2 y. W2 W5 F5 ^' F4 a5 n4 o/ H Gemzar +Cisplatin + Avastin
7 X+ P4 a' x- l$ o+ C' e! Bhttp://annonc.oxfordjournals.org/content/21/9/1804.full% b" e( V8 `. W. V
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) # u( i! {1 V6 V' B
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. 8 W |" o# K' j7 C9 ^
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
" G9 L* B6 w' L1 v' ]
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 636)
) M. Z2 d# N7 q- f华为网盘附件：; ]" s& q/ x0 [/ Q% _) O4 i
【华为网盘】ava.JPG
8 x4 b* k, r' g+ K! r |
显身卡
